Imatinib treatment of ankylosing spondylitis in a patient resistant to NSAIDs and infliximab

Journal of Clinical Rheumatology

Volumn 16, Issue 3, 2010, Pages 140-142

  Nazarinia, Mohammad Ali ^a   Ghaffarpasand, Fariborz ^b   Seraj, Seyed Reza ^b   Heiran, Hamid Reza ^b   Khojasteh, Habib Nourani ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b FASA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; IMATINIB; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT;

ANKYLOSING SPONDYLITIS; ARTICLE; ENTHESITIS; FEVER; LOW BACK PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS RADIOGRAPHY; PRIORITY JOURNAL; SACROILIITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; DRUG RESISTANCE; HUMANS; MALE; PIPERAZINES; PYRIMIDINES; SPONDYLITIS, ANKYLOSING;

EID: 77951066656     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3181d5974f     Document Type: Article

References (17)

1. Paniagua RT, Robinson WH. Imatinib for the treatment of rheumatic diseases. Nat Clin Pract Rheumatol. 2007;3:190-191.
2. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006;354:2667-2676.
3. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med. 2005;353:1412-1413. (Pubitemid 41362714)
4. Eklund KK, Remitz A, Kautiainen H, et al. Three months treatment of active spondyloarthritis with imatinib mesylate: an open-label pilot study with six patients. Rheumatology (Oxford). 2006;45:1573-1575.
5. Eklund KK, Lindstedt K, Sandler C, et al. Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis. J Clin Rheumatol. 2008;14:294-296.
6. Vernon MR, Pearson L, Atallah E. Resolution of rheumatoid arthritis symptoms with imatinib mesylate. J Clin Rheumatol. 2009;15:267.
7. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of New York criteria. Arthritis Rheum. 1984;27:361-368.
8. Mander M, Simpson JM, McLellan A, et al. Studies with enthesis index as a method for clinical assessment in ankylosing spondylitis. Ann Rheum Dis. 1987;46:197-202.
9. Nazarinia MA, Ghaffarpasand F, Heiran HR, et al. Pattern of ankylosing spondylitis in an Iranian population of 98 patients. Mod Rheumatol. 2009; 19:309-315.
10. Au WY, Caguioa PB, Chuah C, et al. Chronic myeloid leukemia in Asia. Int J Hematol. 2009;89:14-23.
11. Miyachi K, Ihara A, Hankins RW, et al. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol. 2003;22:329-332.
12. Eklund KK, Joensuu H. Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases. Ann Med. 2003;35: 362-367.
13. Hansen RA, Gartlehner G, Powell GE, et al. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol. 2007;5:729-735.
14. Juurikivi A, Sandler C, Lindstedt K, et al. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann Rheum Dis. 2005;64: 1126-1131.
15. Sandler C, Joutsiniemi S, Lindstedt KA, et al. Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts. Biochem Biophys Res Commun. 2006;347:31-35.
16. Pham T. Pathophysiology of ankylosing spondylitis: what's new? Joint Bone Spine. 2008;75:656-660.
17. Ando W, Hashimoto J, Nampei A, et al. Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). Bone Miner Metab. 2006;24:274-282.